ORKA Stock Analysis: Buy, Sell, or Hold?
ORKA - Oruka Therapeutics, Inc. Common Stock
$87.47
2.91 (3.44%)
▲
5d:
+3.51%
30d:
+27.75%
90d:
+42.51%
BUY
HIGH Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 10, 2026
25d
Get Alerted When ORKA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ORKA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: ORKA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: ORKA is currently trading at $87.47, which is considered slightly high relative to its 30-day fair value range of $69.20 to $89.77.
Technical Outlook: Technically, ORKA is in a strong uptrend. Immediate support is located at $81.15, while resistance sits at $97.78. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $144.67 (+65.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ORKA is in a strong uptrend. Immediate support is located at $81.15, while resistance sits at $97.78. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $144.67 (+65.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$69.20 -
$89.77
Company Quality Score
59/100
(HOLD)
Options IV Signal
14th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
77.9%
All Signals
- BULLISH: Options cheap (IV 14th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.4%)
- BULLISH: Trading 65.4% below Wall St target ($144.67)
Trading Range Analysis
30-Day Trading Range
$69.20 -
$89.77
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$11.30
(12.9%)
Support & Resistance Levels
Support Level
$81.15
Resistance Level
$97.78
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-35.10
Wall Street Target
$144.67
(+65.4%)
Share & Embed Analysis
Last updated: July 14, 2026 9:12 PM ET
Data refreshes hourly during market hours. Next update: 10:12 PM
Data refreshes hourly during market hours. Next update: 10:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORKA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Joana Goncalves
SELL
7000 shares
2026-04-15
Arjun Agarwal
SELL
395 shares
2026-03-16
Joana Goncalves
SELL
7641 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 51 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 55 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 60 HOLD |
